Top 10 Moonshots
Risk Level: 🔴 High — These stocks can move dramatically on breakthroughs, contracts, funding news, or shifts in investor sentiment.
At a Glance
- Theme: High-risk, high-reward moonshot stocks pursuing frontier technologies
- Data lens: Public market data and company disclosures, reviewed as of January 2026
- Ranking method: Ordered by market capitalization for consistency, not expected returns
These moonshot stocks represent some of the most speculative opportunities in the public markets. Each company operates at the edge of emerging technology, where breakthroughs can drive massive upside, but setbacks can be severe. This list is built for investors who understand that extreme risk and extreme reward often go hand in hand. For a one-page view of everything we track, visit our
Top 10 Rankings hub.
Jump to: How to Use · FAQ
Why Moonshots Belong in Every Investor’s Portfolio
Moonshot stocks attract investors who are willing to accept uncertainty in exchange for asymmetric upside. Unlike blue-chip or defensive companies, these businesses often have unproven business models, limited revenue visibility, or technologies that may take years to commercialize. When progress accelerates, however, the market response can be swift and dramatic. Many investors pair moonshots with more stable allocations, such as Top 10 Blue-Chip Stocks or Top 10 Defensive Stocks, using speculative positions as optional upside rather than portfolio anchors. Others view them similarly to Top 10 Meme Stocks, where sentiment and narrative can dominate fundamentals for extended periods. Behaviorally, moonshots tap into the same instincts that drive interest in Top 10 Growth Stocks and Top 10 AI Stocks, but with far less margin for error. This makes position sizing, patience, and risk awareness essential.
The Top Moonshots for 2026
Updated: January 12, 2026
This list features speculative stocks with elevated risk and high volatility. For clarity and consistency, entries are displayed in order of market capitalization as of the publication date. We strongly encourage readers to conduct their own research before making any investment decisions and consult with a qualified professional.
IonQ sits at the front of the moonshot pack because it represents a direct bet on commercially viable quantum computing, one of the most ambitious technology frontiers today. The company is not trying to incrementally improve existing systems, it is attempting to build machines that could eventually solve problems classical computers cannot touch. That vision explains both the excitement and the extreme volatility investors see in the stock.
IonQ’s appeal is rooted in first-mover credibility and real revenue traction, even though profitability remains far away. The company already sells quantum access through cloud platforms, which gives it a clearer commercialization path than many theoretical peers. For moonshot investors, IonQ is less about near-term earnings and more about whether it becomes a foundational player in a future computing paradigm.
SoundHound AI is a pure-play bet on voice-powered artificial intelligence becoming embedded in everyday products, from cars to restaurants to enterprise software. Instead of building generic chatbots, the company focuses on real-time, voice-first AI that can understand intent, context, and commands in noisy, real-world environments. That narrow focus explains both its strong growth narrative and its ongoing losses.
The stock attracts moonshot investors because SoundHound is already deployed commercially, not just in pilot projects. Major automotive and enterprise partnerships give it credibility, but scaling revenue fast enough to justify valuation remains the central challenge. For investors, SOUN is a wager on voice AI becoming a core interface layer rather than a novelty feature.
Intuitive Machines is a moonshot built around one of the hardest frontiers in modern engineering, commercial lunar and space infrastructure. The company is not a traditional defense contractor or satellite operator. Instead, it focuses on building and operating lunar landers, space communications systems, and mission services tied directly to NASA and future commercial space activity.
What makes LUNR compelling for speculative investors is that it already operates in the real world, not just on whiteboards. Successful lunar missions instantly validate the business model, while failures can erase confidence just as quickly. This binary outcome profile is exactly what defines a true moonshot stock.
BigBear.ai is a moonshot rooted in applied artificial intelligence for decision-making in complex, high-stakes environments. Rather than chasing consumer AI hype, the company focuses on analytics, autonomous systems, and AI-driven insights for defense, intelligence, and critical infrastructure clients. That positioning gives BBAI credibility, but it also ties the company’s fortunes to long sales cycles and government budgets.
For speculative investors, the appeal is that BigBear.ai already operates at scale with real customers and recurring contracts. The risk is that execution missteps or delayed awards can quickly pressure results. This stock fits the moonshot category because success depends on turning strategic relevance into durable, profitable growth.
Quantum Computing Inc. represents one of the most speculative expressions of the quantum computing theme. Unlike larger peers that focus on building full-stack quantum hardware, QUBT positions itself around software, algorithms, and hybrid approaches designed to work across different quantum and classical systems. That strategy lowers capital intensity, but it also increases uncertainty around long-term differentiation.
For moonshot investors, QUBT is appealing precisely because it operates at the edge of what is commercially proven. Revenue today is minimal, but the company’s technology roadmap targets optimization problems that could become valuable if quantum adoption accelerates. This is not a steady-growth story, it is a high-optionality bet on timing and relevance.
Recursion Pharmaceuticals is a moonshot at the intersection of artificial intelligence, automation, and drug discovery. Instead of relying on slow, trial-and-error biology, the company uses massive datasets, machine learning, and robotics to systematically search for new medicines. The promise is speed and scale, finding treatments that traditional research models might never uncover.
For investors, RXRX is compelling because it is not just a biotech company waiting on a single drug. It is building a discovery platform designed to generate many shots on goal over time. The risk is that translating AI-driven discoveries into approved drugs is expensive, slow, and uncertain, which keeps losses high and sentiment volatile.
Aeva Technologies is a moonshot built around next-generation sensing, specifically frequency-modulated continuous wave (FMCW) lidar. Unlike traditional lidar systems that only measure distance, Aeva’s technology also captures velocity at the same time. That capability matters for autonomous driving and advanced robotics, where understanding how fast objects are moving is just as important as knowing where they are.
For speculative investors, AEVA stands out because its technology aims to leapfrog existing lidar approaches rather than compete on price alone. The challenge is timing. Adoption depends on autonomous systems moving from pilots to large-scale deployment, which has proven slower and more uneven than early optimism suggested.
ASP Isotopes is a moonshot built around a highly specialized and often overlooked corner of advanced materials, isotope enrichment. The company focuses on producing isotopes used in nuclear energy, medical applications, and industrial processes, areas where supply constraints can be just as important as demand growth. This makes ASPI less about mass-market adoption and more about solving bottlenecks in critical infrastructure.
For speculative investors, the appeal lies in scarcity and strategic relevance. Isotopes are not commodities that can be easily scaled overnight, and geopolitical or supply-chain disruptions can dramatically change their value. The risk is that commercialization takes longer than expected and capital requirements remain heavy.
Alpha Tau Medical is a moonshot focused on a radically different approach to cancer treatment using alpha-particle radiation. Instead of conventional radiation that can damage surrounding tissue, the company’s technology aims to deliver highly targeted doses designed to destroy tumors while limiting collateral damage. If successful, this approach could reshape how certain solid tumors are treated.
For speculative investors, DRTS stands out because the science is differentiated, not incremental. The company is still early in commercialization, which means progress is measured more by clinical milestones than revenue. That makes the stock highly sensitive to trial updates and regulatory signals.
Arqit Quantum is a moonshot focused on securing the future of digital communication in a world where quantum computers could eventually break today’s encryption. Instead of building quantum hardware, the company concentrates on quantum-safe encryption software designed to protect data against both current and future threats. That positioning makes ARQQ less about raw computing power and more about cybersecurity relevance.
For speculative investors, the appeal lies in the urgency of the problem Arqit is trying to solve. Governments, enterprises, and critical infrastructure operators are increasingly aware of “harvest now, decrypt later” risks. The challenge is converting that awareness into durable, recurring revenue at scale.
5 quick questions • 60 seconds
How to Use This List
Start small: treat moonshots as speculative positions, not core holdings.
Focus on catalysts: track news tied to product milestones, contracts, or regulatory progress.
Expect volatility: large swings are normal, both up and down.
Balance risk elsewhere: offset exposure with steadier areas like Top 10 Dividend Stocks or Top 10 Value Stocks.
Review regularly: moonshot theses can change quickly, so reassessment matters.
How We Chose These Stocks
This list This list focuses on publicly traded companies pursuing frontier technologies such as quantum computing, artificial intelligence, space infrastructure, advanced sensing, and experimental biotech. Each stock represents a business where future outcomes are highly uncertain, but where success could meaningfully reshape an industry. Rather than relying on traditional screeners, selections are made through thematic and editorial review. Emphasis is placed on innovation depth, identifiable catalysts, capital access, and market narratives that can rapidly reprice expectations. Stocks are ranked by market capitalization at the time of publication to provide a consistent and transparent ordering, not as a forecast of future returns. Because of their risk profile, moonshot stocks are best understood alongside broader market exposure. Many investors balance these positions with diversified vehicles like Top 10 Total Market ETFs or targeted allocations such as Top 10 Technology Stocks and Top 10 Small-Cap Stocks.
This overview explains the criteria specific to this list. For a detailed explanation of how Impartoo’s Top 10 lists are researched, curated, and reviewed across all categories, see our Methodology.
Frequently Asked Questions
What is cash burn and runway?
What: cash burn is how much money a company spends each period; runway is how long its cash can last.
How: divide cash on hand by quarterly burn to estimate how many months remain.
Why: a short runway increases the risk of dilution or business failure.
What is dilution?
What: dilution happens when a company issues new shares and existing ownership shrinks.
How: new shares are sold to raise capital, spreading ownership across more investors.
Why: dilution can reduce upside even if the company’s technology succeeds.
What does pre-revenue or early-revenue mean?
What: it describes companies that generate little or no recurring revenue yet.
How: they may rely on prototypes, pilot programs, or research funding instead of sales.
Why: limited revenue increases uncertainty but also leaves room for explosive growth.
What is a binary outcome investment?
What: a binary outcome means results tend to be very good or very bad.
How: success depends on a single breakthrough, approval, or contract.
Why: moonshot stocks often swing sharply because outcomes are not gradual.
Why are moonshot stocks so volatile?
What: their prices can change dramatically in short periods.
How: news, rumors, funding updates, or sentiment shifts can rapidly reprice expectations.
Why: uncertainty amplifies both optimism and fear.
How much of a portfolio should be in moonshot stocks?
What: only a small portion for most investors.
How: many limit exposure to single-digit percentages of total assets.
Why: large losses are possible, even if the upside is attractive.
Why do moonshot stocks often rally on news but fade later?
What: prices jump quickly after announcements.
How: excitement builds faster than real revenue or execution.
Why: expectations reset once timelines and risks become clearer.
How long does it usually take for a moonshot thesis to play out?
What: timelines are often measured in years, not months.
How: technology development, approvals, and commercialization take time.
Why: patience is required, and outcomes may change along the way.
How should investors track moonshot stocks after buying?
What: focus on progress, not daily price moves.
How: monitor cash levels, milestones, contracts, and management updates.
Why: fundamentals matter more than short-term volatility.
Why do many moonshot stocks fail?
What: most do not achieve their original vision.
How: funding dries up, technology stalls, or competition accelerates.
Why: high innovation risk means failure is common, even with strong ideas.
Final Thoughts on Moonshot Investing
Moonshot stocks sit at the far edge of the risk spectrum. These companies are often early in their journeys, with uncertain timelines, evolving business models, and outcomes that may hinge on a single breakthrough or contract. When progress accelerates, returns can be outsized, but when expectations slip, losses can be swift and severe. For most investors, moonshots work best as small, intentional positions, paired with more stable exposure elsewhere in a portfolio. If you’re drawn to innovation and asymmetric upside, this list offers a curated starting point, but discipline, diversification, and patience matter just as much as optimism. If you prefer speculative upside with broader diversification, consider exploring thematic funds like innovation or technology ETFs. If steadier growth is the goal, long-term stock lists may be a better fit.
Explore More Stock Strategies
Prefer a lower-maintenance sleeve alongside moonshots? See Top 10 Set-and-Forget Stocks. Looking to expand your portfolio with other curated strategies? Explore our additional Top 10 lists covering income, value, growth, and sector-specific plays. Every list is built using the same editorial approach and grounded in real market data.
Stay Ahead with Impartoo Insights
Get our latest stock lists, curated investment ideas, and market insights — straight to your inbox.
No hype. Just smart investing.